The Biden administration asked a federal appeals court on November 23 to lift a court-ordered stay on a sweeping workplace Covid-19 vaccine rule to avoid serious harm to public health, or alternatively to allow a masking-and-testing requirement.
If you are not happy with the results below please do another search
50 search results for:
The U.S. Food and Drug Administration approved Takeda Pharmaceutical Co. Ltd.’s drug Livtencity for a common type of viral infection occurring in patients after organ transplant.
The World Health Organization said on November 23 an additional 700,000 people could die from Covid-19 in Europe by March 2022, taking the total to above 2.2 million, as the WHO urged people to get vaccinated and to have booster shots.
The Food and Drug Administration cleared the way for Tonix Pharmaceuticals to begin a Phase II study of the company’s therapeutic candidate, which intends to prevent migraine headaches.
The U.S. Food and Drug Administration greenlit Aadi Bioscience’s Fyarro for treating a rare and aggressive form of cancer that disproportionately affects women.
Glympse Bio has developed a liquid biopsy with the potential to diagnose and monitor non-alcoholic steatohepatitis (NASH) with significantly higher accuracy and less invasiveness than needle biopsies, according to a late-breaking presentation at the American Association for the Study of Liver Disease (AASLD) annual The Liver Meeting.
New discovery facilities have been launched in the biotech space by AstraZeneca, BeiGene, and NeuExcell Therapeutics.
An experimental chewing gum containing a protein that “traps” coronavirus particles could limit the amount of virus in saliva and help curb transmission when infected people are talking, breathing or coughing, researchers believe. In other news, protection against Covid-19 from an mRNA vaccine – either the Moderna or Pfizer/BioNTech shots – may last longer after the booster dose than after the original two-shot regimen, researchers speculated based on the results of a small new study.
JAMA Neurology published a study by researchers looking at cases of amyloid-related imaging abnormalities (ARIA-E) in two Phase III trials for Biogen’s Alzheimer’s drug Aduhelm (aducanumab).
Arrowhead Pharmaceuticals Inc. on November 22 entered a drug development deal with GlaxoSmithKline Plc under which the British drugmaker will develop and market Arrowhead’s potential treatment for patients with fatty liver disease NASH.